Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice

Wassihun Wedajo Aragaw; Christine Roubert; Evelyne Fontaine; Sophie Lagrange; Matthew D. Zimmerman; Véronique Dartois; Martin Gengenbacher; Thomas Dick

doi:10.1128/AAC.01400-21

Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice

Wassihun Wedajo Aragaw
, Christine Roubert
, Evelyne Fontaine
, Sophie Lagrange
, Matthew D. Zimmerman
, Véronique Dartois
, Martin Gengenbacher
, Thomas Dick

Center for Discovery and Innovation

Center for Discovery and Innovation
Evotec ID

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Cyclohexyl-griselimycin is a preclinical candidate for use against tuberculosis (TB). Here, we show that this oral cyclodepsipeptide is also active against the intrinsically drug-resistant nontuberculous mycobacterium Mycobacterium abscessus in vitro and in a mouse model of infection. This adds a novel advanced lead compound to the M. abscessus drug pipeline and supports a strategy of screening chemical matter generated in TB drug discovery efforts to fast-track the discovery of novel antibiotics against M. abscessus.

Original language	English
Article number	e01400-21
Journal	Antimicrobial Agents and Chemotherapy
Volume	66
Issue number	1
DOIs	https://doi.org/10.1128/AAC.01400-21
State	Published - Jan 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

DnaN
Griselimycin
Mycobacterium abscessus
Nontuberculous mycobacteria
NTM

Access to Document

10.1128/AAC.01400-21

Cite this

@article{e6eb5a497ccf43989802e23976cf615a,

title = "Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice",

abstract = "Cyclohexyl-griselimycin is a preclinical candidate for use against tuberculosis (TB). Here, we show that this oral cyclodepsipeptide is also active against the intrinsically drug-resistant nontuberculous mycobacterium Mycobacterium abscessus in vitro and in a mouse model of infection. This adds a novel advanced lead compound to the M. abscessus drug pipeline and supports a strategy of screening chemical matter generated in TB drug discovery efforts to fast-track the discovery of novel antibiotics against M. abscessus.",

keywords = "DnaN, Griselimycin, Mycobacterium abscessus, Nontuberculous mycobacteria, NTM",

author = "Aragaw, \{Wassihun Wedajo\} and Christine Roubert and Evelyne Fontaine and Sophie Lagrange and Zimmerman, \{Matthew D.\} and V{\'e}ronique Dartois and Martin Gengenbacher and Thomas Dick",

note = "Publisher Copyright: {\textcopyright} 2022 Aragaw et al.",

year = "2022",

month = jan,

doi = "10.1128/AAC.01400-21",

language = "English",

volume = "66",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "1",

}

TY - JOUR

T1 - Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice

AU - Aragaw, Wassihun Wedajo

AU - Roubert, Christine

AU - Fontaine, Evelyne

AU - Lagrange, Sophie

AU - Zimmerman, Matthew D.

AU - Dartois, Véronique

AU - Gengenbacher, Martin

AU - Dick, Thomas

PY - 2022/1

Y1 - 2022/1

N2 - Cyclohexyl-griselimycin is a preclinical candidate for use against tuberculosis (TB). Here, we show that this oral cyclodepsipeptide is also active against the intrinsically drug-resistant nontuberculous mycobacterium Mycobacterium abscessus in vitro and in a mouse model of infection. This adds a novel advanced lead compound to the M. abscessus drug pipeline and supports a strategy of screening chemical matter generated in TB drug discovery efforts to fast-track the discovery of novel antibiotics against M. abscessus.

AB - Cyclohexyl-griselimycin is a preclinical candidate for use against tuberculosis (TB). Here, we show that this oral cyclodepsipeptide is also active against the intrinsically drug-resistant nontuberculous mycobacterium Mycobacterium abscessus in vitro and in a mouse model of infection. This adds a novel advanced lead compound to the M. abscessus drug pipeline and supports a strategy of screening chemical matter generated in TB drug discovery efforts to fast-track the discovery of novel antibiotics against M. abscessus.

KW - DnaN

KW - Griselimycin

KW - Mycobacterium abscessus

KW - Nontuberculous mycobacteria

KW - NTM

UR - https://www.scopus.com/pages/publications/85123069190

U2 - 10.1128/AAC.01400-21

DO - 10.1128/AAC.01400-21

M3 - Article

C2 - 34723632

AN - SCOPUS:85123069190

SN - 0066-4804

VL - 66

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 1

M1 - e01400-21

ER -

Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this